Search research articles
Contact Us
Filters
Showing results (101-110 of 124) with videos related to
Page
of 13
Sort By:
Bone Marrow Transplantation
|
January 7, 1998
Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan)
E Deconinck, J Y Cahn, N Milpied, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2005
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies
C Foussard, P Colombat, H Maisonneuve, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma
F Morschhauser, C Recher, N Milpied, et al.
Leukemia & Lymphoma
|
April 1, 1997
Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte
C Gisselbrecht, C Haioun, E Lepage, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 12, 2012
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up
P Colombat, N Brousse, G Salles, et al.
Hematology and Cell Therapy
|
May 27, 1999
Low dose T-cell lymphocyte infusion combined with marrow T-cell depletion as prophylaxis of acute graft vs host disease for HLA identical sibling bone marrow transplantation
J Y Cahn, E Deconinck, P Tiberghien, et al.
Blood
|
October 25, 2001
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease
V Leblond, V Lévy, F Maloisel, et al.
Talanta
|
December 23, 2021
GEONs API fingerprint project: Selection of analytical techniques for clustering of sildenafil citrate API samples
E Deconinck, P Courselle, M Raimondo, et al.
Blood
|
January 3, 2001
Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft
P Tiberghien, C Ferrand, B Lioure, et al.
Blood
|
October 1, 1996
A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group
E Wattel, A Guerci, B Hecquet, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 124) with videos related to
Sort By:
Page
of 13
Bone Marrow Transplantation
|
January 7, 1998
Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan)
E Deconinck, J Y Cahn, N Milpied, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2005
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies
C Foussard, P Colombat, H Maisonneuve, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma
F Morschhauser, C Recher, N Milpied, et al.
Leukemia & Lymphoma
|
April 1, 1997
Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte
C Gisselbrecht, C Haioun, E Lepage, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 12, 2012
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up
P Colombat, N Brousse, G Salles, et al.
Hematology and Cell Therapy
|
May 27, 1999
Low dose T-cell lymphocyte infusion combined with marrow T-cell depletion as prophylaxis of acute graft vs host disease for HLA identical sibling bone marrow transplantation
J Y Cahn, E Deconinck, P Tiberghien, et al.
Blood
|
October 25, 2001
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease
V Leblond, V Lévy, F Maloisel, et al.
Talanta
|
December 23, 2021
GEONs API fingerprint project: Selection of analytical techniques for clustering of sildenafil citrate API samples
E Deconinck, P Courselle, M Raimondo, et al.
Blood
|
January 3, 2001
Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft
P Tiberghien, C Ferrand, B Lioure, et al.
Blood
|
October 1, 1996
A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group
E Wattel, A Guerci, B Hecquet, et al.
Page
of 13